Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Astellas Strikes Deal to License JAK Inhibitor to Janssen Biotech Outside Japan
Astellas Pharma said on October 2 that it has signed an agreement with Janssen Biotech to grant the US company exclusive rights to develop and commercialize its ASP015K, a Janus kinase (JAK) inhibitor for rheumatoid arthritis, worldwide except for Japan.…
To read the full story
BUSINESS
- MSD Debuts HIV Drug Idvynso in Japan in World-First Launch
April 16, 2026
- GSK’s Long-Acting Asthma Drug Exdensur Now Available in Japan
April 16, 2026
- Shionogi’s CVC Makes First Investment in Restore Vision
April 16, 2026
- Mochida Partners with Qilu on Gonal-f Biosimilar Development
April 16, 2026
- Astellas Kicks Off Global PIII of KRAS G12D Degrader Setidegrasib
April 16, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…